For Immediate Release

 Contact: info@globalcancertechnology.com

CHINA ISSUES GLOBAL CANCER TECHNOLOGY PATENT FOR GCT-007 BROADENS IP PROTECTION IN ASIA FOR PROPRIETARY PI3K INHIBITOR DRUG

San Diego, CA, March 13, 2024—Global Cancer Technology, Inc. announced today that the China Patent Office has granted patent protection (Patent No. ZL201980032054) to the Company’s drug compound, GCT-007, a potent small-molecule PI3K inhibitor. Global Cancer Technology has exclusive worldwide licensing rights for GCT-007 from Neuropore Therapies, Inc.

 

“We are delighted that the China Patent Office has recognized the uniqueness of our compound and has granted patent protection”, said John Clark, the CEO of Global Cancer Technology. Mr. Clark further stated, “Adding this newly issued China patent to our IP portfolio solidifies our position for the Asian markets and strengthens the worldwide protection of our IP assets.

 

To-date, the Company has largely focused its preclinical research programs for the small molecule inhibitor on the treatment of glioblastoma and certain forms of treatment-resistant breast cancer. Both are areas of significant unmet medical need and cancers where the PI3K pathway can play an instrumental role in effecting treatment. Presently, no PI3K inhibitors are approved for the treatment of brain cancers in China, where the Glioblastoma Multiforme therapeutics market has been valued at around $0.21 billion in 2022 and is projected to have a CAGR of 10.4%, reaching $0.45 billion by 2030, making it an attractive market for IP protection.

 

————————————————————————————————————————————————————————————————————————————–

Global Cancer Technology is a pre-clinical non-revenue biopharma company that is currently raising investment capital to enter a Phase 1 clinical trial {globalcancertechnology.com}. Statements in this news release may contain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1993 and Section 21E of the Securities and Exchange Act of 1934. Such statements may involve various risks and uncertainties, some of which may be discussed in the Company’s most recent shareholder letter. There is no assurance any new products can be cleared for sale by the FDA or successfully commercialized.